HDAC1
ENSG00000116478
Target class
Epigenetic regulator
Chromosome
1
Approved drugs
5
Clinical candidates (approved and in development)
12
- Approved drugs
- 5
- ClinGen gene-disease validity
- Disputed
- Clinical candidates (approved and in development)
- 12
- Chemical probe available
- Yes
- Target name
- HDAC1
- Gene name
- Histone deacetylase 1
- Gene symbol
- HDAC1
- Previous gene symbols
- RPD3L1
- Protein name
- Histone deacetylase 1 (HD1) (EC 3.5.1.98) (Protein deacetylase HDAC1) (EC 3.5.1.-) (Protein deacylase HDAC1) (EC 3.5.1.-)
- HD1
- GON-10
- KDAC1
- Gene biotype
- Protein coding
- Gene family
- Histone deacetylases, class I|EMSY complex|NuRD complex subunits|SIN3 histone deacetylase complex subunits|CoREST complex subunits|MiDAC complex subunits|MIER complex subunits|RERE complex subunits
- Target class
- Epigenetic regulator
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 226.13
- Tissue specificity (Gini)
- 0.36
- Tissue specificity (tau)
- 0.709
- KEGG gene identifiers
- hsa:3065
- Protein interaction confidence
- 0.879674
- Protein interaction partners
- 334
- R-HSA-1362277
- R-HSA-1362300
- R-HSA-1538133
- R-HSA-193670
- R-HSA-201722
- R-HSA-2122947
- R-HSA-2173795
- R-HSA-2173796
- R-HSA-2644606
- R-HSA-2894862
- R-HSA-3214815
- R-HSA-350054
- R-HSA-3769402
- R-HSA-427389
- R-HSA-427413
- R-HSA-4551638
- R-HSA-4641265
- R-HSA-6804758
- R-HSA-69205
- R-HSA-73762
- R-HSA-8936459
- R-HSA-8943724
- R-HSA-9018519
- R-HSA-9022538
- R-HSA-9022692
And 17 more, listed on the interactive page.
- End position
- 32333635
- Start position
- 32291921
- Chromosome
- 1
- Strand
- Forward
- Nucleus .
- Nucleoplasm
- PubMed 10846170
- PubMed 20523938
- PubMed 28977666
- PubMed 33283408
- Tissue specificity (tau)
- 0.708675
- Expression inequality (Gini)
- 0.359999
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes
- 226.13
- Thyroid
- 134.58
- Ovary
- 129.75
- Spleen
- 125.83
- Small Intestine - Terminal Ileum
- 124.06
Expression in transcripts per million
- Cells - EBV-transformed lymphocytes226.13
- Thyroid134.58
- Ovary129.75
- Spleen125.83
- Small Intestine - Terminal Ileum124.06
- Esophagus - Mucosa123.01
- Cervix - Endocervix122.35
- Cervix - Ectocervix121.46
- Vagina120.16
- Uterus118.22
- Colon - Transverse117.5
- Prostate108.45
- Fallopian Tube103.92
- Cells - Cultured fibroblasts103.02
- Pituitary97.84
- Bladder93.58
- Lung88.05
- Colon - Sigmoid87.58
- Testis85.28
- Minor Salivary Gland83.24
- Stomach77.55
- Esophagus - Gastroesophageal Junction77.28
- Nerve - Tibial76.35
- Artery - Tibial76.12
- Esophagus - Muscularis74.26
And 29 more, listed on the interactive page.
- GO:0000122
- GO:0006325
- GO:0006338
- GO:0006346
- GO:0006357
- GO:0008284
- GO:0010629
- GO:0010832
- GO:0033148
- GO:0043066
- GO:0043922
- GO:0045814
- GO:0045892
- GO:0045893
- GO:0045944
- GO:0060766
- GO:0090090
- GO:0000118
- GO:0000785
- GO:0005634
- GO:0005654
- GO:0005737
- GO:0005829
- GO:0016581
- GO:0032991
- GO:0070822
- GO:0000978
- GO:0000979
- GO:0001046
- GO:0001222
- GO:0002039
- GO:0003714
- GO:0004407
- GO:0005515
- GO:0019899
- GO:0031492
- GO:0033558
- GO:0042826
- GO:0051059
- GO:0061629
- GO:0140297
- GO:0141221
- GO:0160008
- GO:0160009
- GO:0160216
Neural tube defects
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- organ
Evidence sourceNeural tube defects
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- organ
Evidence sourceFacial cartilage structures are reduced in size and morphologically distorted
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- organ
Evidence sourceTesticular atrophy
Effects
- Inhibition/Decrease/Downregulation
Studies
- cell-based
Biological samples
- organ
Evidence source
regulation of transcription factor activity
Studies
- cell-based: TOX21_HDAC_Inhibition is one of one assay component(s) measured or calculated from the TOX21_HDAC_Inhibition assay. It is designed to make measurements of HDAC activity as detected with bioluminescence signals by luciferase-coupled ATP quantitation technology.
Biological samples
- HCT-116, cell line
Evidence source
Related records
Trials (805)
- 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat
- A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
- A Clinical Study on Prophylactic RespOnse To hEtrombopag for Secondary Prevention in Anti-Cancer Therapy-induced Thrombocytopeniae
- A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients
- A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma (0683-004)
- A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED)
- A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
- A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Aerodigestive Tract Cancer
- A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
- A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer (0683-070)(COMPLETED)
- A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
- A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer
- A Dose Ranging Placebo-controlled Double-blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of 610 in Participants With Severe Eosinophilic Asthma
- A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.
- A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)
- A Multi-Center Phase 2 Study to Evaluate Efficacy and Safety of Oral Abexinostat as Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
- A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.
- A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis
- A Panobinostat Presurgery
Drugs (14)
- Abexinostat Histone deacetylase inhibitor
- Belinostat Histone deacetylase inhibitor
- CUDC-101 Histone deacetylase inhibitor
- Entinostat Histone deacetylase inhibitor
- Fimepinostat Histone deacetylase inhibitor
- Givinostat Histone deacetylase inhibitor
- Givinostat hydrochloride Histone deacetylase inhibitor
- Mocetinostat Histone deacetylase 1 inhibitor
- Panobinostat Histone deacetylase inhibitor
- Panobinostat lactate Histone deacetylase inhibitor
- Quisinostat Histone deacetylase inhibitor
- Romidepsin Histone deacetylase inhibitor
- Tacedinaline Histone deacetylase inhibitor
- Vorinostat Histone deacetylase 1 inhibitor